JUVE Comment

This French patent litigation practice led by the renowned Thomas Bouvet has recently strengthened its position as a sought-after, experienced outfit whilst competitors grapple with declining caseloads. Jones Day handles patent litigation for regular clients such as Coloplast and new clients including Wybotics.

Beyond its established specialism in pharmaceuticals, biotechnology and medical device manufacture, the team maintains expertise across a wide range of technologies. The practice recently bolstered its team with an experienced dual-qualified associate. This appointment strengthens its Paris practice for UPC cases while also filling a gap in the team’s own line-up, though this had been less significant due to close collaboration with Jones Day patent attorneys in Germany.

The French team has made notable progress in this arena. For instance, Bouvet is leading the case for SEB in proceedings against SharkNinja at the Paris local division and co-leading matters for Ecovacs and Peri alongside the German team. The team draws on experience gained working with German colleagues in joint work, as well as providing background support in a matter alongside Hogan Lovells for Reel.

Strengths

Integrated patent litigation in Europe and the US. Litigation concerning SPCs and plant protection.

Recommended individuals

Thomas Bouvet

Team

4 lawyers, 1 dual qualified

Clients

Litigation: Coloplast against Hollister over urinary catheters; Daiichi Sankyo against six generic drug companies on SPC for anti-cholesterol medication; Schwind against Carl Zeiss over laser eye surgery (settled 2025); Infineon against Intellectual Ventures over SEPs; Lufthansa Technik against Astronics, Panasonic and Thales Avionics over aeroplane seats; Illinois Tool Works and Instron against BIA over car-crash-test catapults; Terraillon against Withings over connected scales; Terraillon against Leifheit regarding scales; Wybotics against Zodiac over pool cleaning robots; The Trustees of the University of Pennsylvania over refusal by the French Patent Office to grant an SPC on Onasemnogene abeparvovec/Zolgensma; Starfruit in complaint about revocation of community plant variety right at the Board of Appeal of the Community Plant Variety Office.